NuPathe to Present at the 2011 Wedbush Securities Life Sciences: Management Access Conference

NuPathe to Present at the 2011 Wedbush Securities Life Sciences: Management Access Conference

ID: 43893

(firmenpresse) - CONSHOHOCKEN, PA -- (Marketwire) -- 08/09/11 -- NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that , chief executive officer, will present a company overview at the 2011 Wedbush Securities Life Sciences: Management Access Conference on Tuesday, August 16, 2011 at 12:40 p.m. EDT. The conference is being held at Le Parker Meridien in New York, NY.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, . Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for 90 days following the call.

NuPathe Inc. () is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, , is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates: for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and in preclinical development for the long-term treatment of schizophrenia and bipolar disorder.



John Woolford
(443) 213-0506


Keith A. Goldan
Vice President, Chief Financial Officer
NuPathe Inc.
(484) 567-0130



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Alethia Biotherapeutics Announces Issuance of its Second Therapeutic Target Patent Stemming From its Proprietary Target Discovery Platform Second Genome Announces Series A Financing
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 09.08.2011 - 12:30 Uhr
Sprache: Deutsch
News-ID 43893
Anzahl Zeichen: 0

contact information:
Town:

CONSHOHOCKEN, PA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 208 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"NuPathe to Present at the 2011 Wedbush Securities Life Sciences: Management Access Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

NuPathe Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von NuPathe Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z